REVENUE RECOGNITION - Schedule of net revenue from collaborative arrangements (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Revenue Recognition and Collaborative Arrangements
Total royalty revenue	$ 310,463	$ 331,339	$ 391,866
Royalty revenue
Revenue Recognition and Collaborative Arrangements
Less: amortization of capitalized fees paid	(13,800)	(13,800)	(13,800)
Total royalty revenue	238,846	311,645	391,866
GSK
Revenue Recognition and Collaborative Arrangements
Total royalty revenue	238,846	311,645	391,866
GSK | Royalty revenue
Revenue Recognition and Collaborative Arrangements
Royalties	252,669	325,468	405,689
Less: amortization of capitalized fees paid	(13,823)	(13,823)	(13,823)
GSK | RELVAR/BREO
Revenue Recognition and Collaborative Arrangements
Royalties	208,042	215,034	234,066
GSK | ANORO
Revenue Recognition and Collaborative Arrangements
Royalties	44,627	38,405	44,935
GSK | TRELEGY
Revenue Recognition and Collaborative Arrangements
Royalties	$ 0	$ 72,029	$ 126,688